J&J collaborates with Vibalogics on COVID-19 vaccine development

18 May 2020

Global contract development and manufacturing organization (CDMO) Vibalogics is to manufacture additional clinical trial material for Johnson & Johnson’s (NYSE: JNJ) lead COVID-19 vaccine candidate.

The German firm, which specializes in the production of virotherapy products, is working with J&J’s pharmaceutical arm, Janssen Pharmaceutical, on the project.

The trial material will be produced at the company’s GMP-accredited facility in Cuxhaven, with the goal of delivering many thousands of doses of the investigational COVID-19 vaccine candidate.

Chief executive Stefan Beyer said: “This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK